玻璃腔内注射曲安奈德联合真武汤加减治疗视盘血管炎继发黄斑水肿的临床疗效观察

目的:探讨玻璃腔内注射曲安奈德结合真武汤加减治疗视盘血管炎继发黄斑水肿的临床疗效及安全性。方法:选择2013年12月到2017年4月在我院诊治的视盘血管炎继发黄斑水肿患者142例(142眼)作为研究对象,根据信封随机抽签法分为观察组与对照组,每组各71例。对照组给予玻璃腔内注射曲安奈德治疗,观察组在对照组治疗的基础上给予真武汤加减治疗。治疗1个月后,比较两组治疗前后视力、黄斑中心凹厚度的变化情况及不良反应的发生情况。结果:治疗后,观察组与对照组的视力均明显优于治疗前(P0.05),且观察组视力明显优于对照组(P0.05)。治疗后,观察组与对照组的黄斑中心凹厚度分别为168.34±22.19μm和267.35±34.11μm,均明显低于治疗前[516.35±45.20μm和522.14±23.01μm](P0.05),且观察组治疗后黄斑中心凹厚度明显低于对照组(P0.05)。两组治疗后发生玻璃体积血、新生血管性青光眼、瞳孔区模性渗出等并发症,发生率对比差异无统计学意义(P0.05)。结论:与单用玻璃腔内注射曲安奈德治疗相比,玻璃腔内注射曲安奈德结合真武汤加减治疗视盘血管炎继发黄斑水肿的安全性更高,且能有效减轻黄斑水肿,缩小黄斑区域,提高视力。     

温敏性几丁糖填充兔眼玻璃体两种手术方式对比研究

目的:通过两种手术方式对兔眼玻璃体进行温敏性几丁糖填充,比较其眼压及并发症差异。方法:将18只白兔随机分为实验组和对照组,每组各9只,右眼均为手术眼,实验组白兔行玻璃体切割术并注入温敏性几丁糖,对照组通过1 m L注射器抽取玻璃体并填充温敏性几丁糖,术后随访1月,对比两组白兔术后眼压及手术并发症的差异性。结果:实验组手术前眼压(7.76±2.21)mm Hg与术后眼压(7.49±2.98)mm Hg无明显差异(P0.05),对照组手术前眼压(7.80±2.04)mm Hg与手术后眼压(5.17±0.96)mm Hg有统计学意义(P0.05)。对照组术后并发症发生率为44.4%(4/9),明显高于实验组22.2%(2/9)。结论:玻璃体腔注射温敏性几丁糖操作简单,但并发症较多,且易造成眼压改变;而玻璃体切割术后填充温敏性几丁糖并发症相对较少,眼压波动较小,但应注意并发性白内障的发生。     

曲安奈德对年龄相关性白内障患者房水TNF-α、IL-1β、IL-6的影响

目的:探讨曲安奈德对年龄相关性白内障术后患者房水肿瘤坏死因子(TNF)-α、白介素(IL)-1β、IL-6水平的影响。方法:选择2014年6月至2016年6月我院接诊的92例年龄相关性白内障患者,通过随机数表法分为观察组(n=46)和对照组(n=46),均择期行白内障超声乳化吸除联合人工晶状体植入术。观察组在人工晶状体植入后,在前房内注射曲安奈德,对照组注射复方平衡盐液,术后24 h,使用普拉洛芬滴眼液,连续用药1个月。比较两组手术前、手术后7d后眼压、角膜内皮细胞计数、裸眼视力、最佳矫正视力、眼部体征积分、炎症因子的变化,手术后1d、手术后7d时前房反应及不良反应的发生情况。结果:两组手术前后眼压、角膜内皮细胞计数均未发生明显变化(P0.05);手术后,两组裸眼视力、最佳矫正视力、眼部体征积分均较治疗前明显改善(P0.05),观察组裸眼视力、最佳矫正视力、眼部体征积分明显优于对照组(P0.05);与手术前相比,两组房水中TNF-α、IL-1β、IL-6水平均显著降低(P0.05),观察组房水TNF-α、IL-1β、IL-6水平均明显低于对照组(P0.05);观察组在手术后1d、7d时前房反应1级比例均高于对照组,前房反应3级、4级比例均比对照组低(P0.05);观察组不良反应总发生率明显低于对照组(P0.05)。结论:曲安奈德用于年龄相关性白内障患者术后患者的效果显著,其可有效缓解术后前葡萄膜炎,减少并发症,促进术后视力恢复,其机制可能与抑制房水中TNF-α、IL-1β、IL-6的表达相关。     

康柏西普与雷珠单抗对年龄相关性黄斑变性患者血清CRP、VEGF、眼压及视力的影响

目的:探讨康柏西普与雷珠单抗对年龄相关性黄斑变性(AMD)患者血清中C反应蛋白(CRP)、血管内皮生长因子(VEGF)水平、眼压(IOP)及视力的影响。方法:选取2015年4月到2016年5月在我院接受治疗的AMD患者70例作为研究对象,采用随机数字表法将所有患者分为观察组和对照组各35例,所有患者给予内眼手术标准玻璃体注射治疗,观察组给予康柏西普注射液1.5mg腔内注射,对照组给予雷珠单抗注射液0.5 mL腔内注射,对比两组患者治疗前、治疗后3d血清CRP、VEGF水平;记录并对比两组患者视力、IOP水平及并发症情况。结果:两组患者治疗后3d血清CRP、VEGF水平较治疗前下降,且观察组患者CRP、VEGF水平低于对照组(P0.05);两组患者治疗后3d视力最小视角对数(logMAR)及IOP较治疗前降低,且观察组患者视力logMAR及IOP水平明显低于对照组,差异均有统计学意义(P0.05)。治疗后3d,两组各出现1例玻璃体出血,并发症发生率比较差异无统计学意义(P0.05)。结论:相对于雷珠单抗,康柏西普更能有效降低AMD患者血清CRP、VEGF水平和IOP,提高患者视力,改善病情,值得临床推广应用。     

糖尿病白内障术后黄斑水肿与房水细胞因子的关系

为了探讨2型糖尿病白内障术后黄斑水肿与房水中细胞因子的关系,本研究选取2016年2月至2017年7月在我院治疗的2型糖尿病白内障患者117例117眼,均行超声乳化白内障摘除术,观察术后4周黄斑水肿发生情况以及房水中多种细胞因子水平。研究结果显示:术后4周,有37眼发生黄斑水肿(观察组),未发生黄斑水肿80眼(对照组);观察组术后4周黄斑区视网膜厚度为(247.28±18.37)μm,明显高于对照组(p<0.05),且明显高于术前水平(p<0.05);观察组术后4周干扰素诱导蛋白-10 (IP-10)、巨噬细胞趋化蛋白(MCP-1)、血管内皮生长因子(VEGF)和细胞因子转化生长因子-β2 (TGF-β2)水平分别为(6.01±0.89) pg/mL、(340.03±45.39) pg/mL、(812.28±40.06) pg/mL和(40.05±10.03) pg/mL,明显高于对照组(p<0.05),且高于术前水平(p<0.05);观察组和对照组手术前后粒细胞-巨噬细胞集落刺激因子(GM-CSF)和碱性成纤维细胞生长因子(b-FGF)比较差异无统计学意义(p>0.05);术后4周IP-10、MCP-1、VEGF和TGF-β2水平与黄斑区视网膜厚度呈正相关(r=0.452, 0.501, 0.466和0.470, p<0.05)。本研究的结果初步说明,房水中IP-10、MCP-1、VEGF和TGF-2水平与2型糖尿病白内障术后黄斑水肿有一定关系,有可能成为黄斑水肿的特异性评价指标,值得进一步研究。     

康柏西普联合激光光凝治疗糖尿病黄斑水肿43 例临床分析

目的:探讨康柏西普玻璃体腔注射联合激光光凝治疗糖尿病黄斑水肿的临床疗效及安全性。方法:收取2013年6月至2015年8月间我院收治的糖尿病黄斑水肿患者87例(87眼)作为研究对象,采用随机数字表法将其分为观察组及对照组,观察组43例(43眼)给予康柏西普玻璃体腔注射联合激光光凝治疗,对照组44例(44眼)给予单纯激光光凝治疗。对两组患者治疗前后视力(best corrected visual acuilty,BCVA)、视网膜厚度(central macular thickness,CMT)、临床疗效、并发症以及生活质量进行观察与比较。结果:治疗前两组患者BCVA、CMT均无显著差异,治疗后两组BCVA、CMT均有所提高,同时间点观察组明显高于对照组,差异有统计学意义(P0.05)。观察组治疗后6个月视力提高率为81.40%,对照组为13.64%,观察组远高于对照组,差异有统计学意义(P0.05)。观察组患者共有3例出现一过性眼压升高,对照组共有2例患者出现一过性眼压增高,两组相较无统计学差异(P0.05)。观察组生活质量显著高于对照组,差异有统计学意义(P0.05)。结论:康柏西普玻璃体腔注射联合激光光凝治疗糖尿病黄斑水肿具有良好的疗效及安全性,有利于患者生活质量提高,值得临床推广应用。     

玻璃酸钠和曲安奈德治疗膝关节骨性关节炎的疗效比较

目的:比较关节腔内注射玻璃酸钠和曲安奈德治疗膝关节骨性关节炎的疗效。方法:将膝关节骨性关节炎患者随机分为2组,分别接受玻璃酸钠和曲安奈德治疗。随访6个月,评估每组患者的膝关节疼痛评分、关节功能、活动角度。结果:曲安奈德治疗后的第1、2周疼痛缓解作用、关节功能显著优于玻璃酸钠(P<0.05)。2组患者膝关节活动度在治疗后的第1、3个月内无显著差异(P>0.05),玻璃酸钠治疗后的第6个月关节活动度显著优于曲安奈德(P<0.05)。结论:曲安奈德和玻璃酸钠均可缓解膝关节疼痛,改善功能和增加膝关节活动度。曲安奈德早期疗效优于玻璃酸钠,但持续时间较玻璃酸钠短。     

1550nm非剥脱点阵激光治疗斑秃的临床随机对照试验

比较1 550 nm非剥脱点阵激光和醋酸曲安奈德注射液皮损内注射治疗斑秃的临床疗效。将72例斑秃患者随机分成两组,治疗组36例、对照组36例,治疗组用1 550 nm非剥脱点阵激光治疗,对照组用醋酸曲安奈德注射液皮损内注射,每2周1次,共4次,12周后观察结果。治疗12周后治疗组治愈29例(80.5%),显效5例,总有效率94.4%;对照组治愈12例(40.0%),显效8例,总有效率66.7%;治疗组有效率和治愈率显著高于对照组(P0.01和P0.01)。治疗结束后6个月,治疗组复发3例(8.8%);对照组复发5例(25%),两组复发率比较,差异无统计学意义(P0.05)。治疗组的不良反应发生率(8.8%)比对照组(25%)小,不良反应发生率差异有显著性(P0.01)。1 550 nm非剥脱点阵激光治疗斑秃疗效显著。     

羟苯磺酸钙与曲安奈德治疗对DME患者血清VEGF和ICAM-1的影响

为了探讨羟苯磺酸钙与曲安奈德治疗对糖尿病黄斑水肿(DME)患者血清血管内皮生长因子(VEGF)和细胞间黏附分子-1(ICAM-1)的影响,本研究回顾性分析2015年6月至2017年6月间收治的102例(102眼)DME患者临床资料,根据治疗方案分为观察组(n=50)和对照组(n=52)。对照组应用激光光凝治疗+羟苯磺酸钙,观察组应用激光光凝治疗+曲安奈德。评估治疗前、治疗1月及6月时两组患者视力、黄斑中心凹厚度、眼压及血清因子(VEGF,ICAM-1),记录治疗前、治疗6月后两组生活质量[中文版低视力者生活质量量表(CLVQOL)],记录患者不良反应发生率。研究结果表明,治疗1月、6月时,2组BVCA均高于治疗前(p0.05),2组黄斑中心凹厚度、血清因子(VEGF,ICAM-1)指标水平均低于治疗前(p0.05),观察组变动幅度大于对照组(p0.05);治疗前、治疗1月及6月时2组眼压对比,差异均无统计学意义(p0.05);治疗6月后,2组CLVQOL评分均高于治疗前(p0.05),观察组增幅大于对照组(p0.05);两组不良反应发生率对比,差异无统计学意义(p0.05)。本研究初步结论表明:曲安奈德治疗DME在改善患者视力,降低黄斑中心凹厚度及控制VEGF、ICAM-1水平疗效优于羟苯磺酸钙,但两药治疗安全性无差异。     

577nm微脉冲激光联合康柏西普治疗糖尿病性黄斑水肿的临床疗效

目的:研究577nm微脉冲激光联合康柏西普治疗糖尿病性黄斑水肿的临床疗效。方法:选择2012年2月~2014年12月在我院进行诊治的糖尿病性黄斑水肿患者103例(103眼),根据治疗方法的差异分为观察组和对照组。对照组给予577nm微脉冲激光治疗,观察组给予577nm微脉冲激光治疗联合玻璃体腔内注射康柏西普,对比分析两组患者治疗前后最佳矫正视力和黄斑中心凹厚度的变化。结果:经两因素重复测量方差分析,两组的最佳矫正视力和黄斑中心凹厚度在组间的治疗效应与时间效应的交互作用均有明显统计学意义(P0.05),处理主效应也均有明显统计学意义(P0.05),两种治疗方法的疗效有明显的差异(P0.05),观察组的最佳矫正视力和黄斑中心凹厚度指标优于对照组(P0.05)。两组的最佳矫正视力随治疗时间的延长而升高(P0.05),黄斑中心凹厚度随治疗时间的延长而降低(P0.05)。结论:577nm微脉冲激光联合康柏西普能改善糖尿病性黄斑水肿患者的最佳矫正视力,减轻黄斑水肿程度,值得应用推广。     

Effects of endogenous cyclotronic ionic resonance (ICR) on macular diabetic edema: preliminary results

The intent in this research was to verify the effects of the application of low frequency magnetic fields to cases of macular diabetic edema. We treated six patients afflicted by non-proliferating diabetic retinopathy with macular oedema. Quantitative clinical appraisals of the retinal thickness were obtained for the Optical Coherence Tomography (OCT I). None of the cases affected by non-cystoid macular oedema (non-CMO), or with a relevant ischemic component, evidenced by retinal fluorangiography, had further worsening in their clinical course during the treatment. Only one of the patients, who underwent a long treatment period with ICR demonstrated a significant reduction of the macular edema, with no need of other invasive therapeutic procedures (intravitreous injection of triamcinolone and/or laser therapy).     

Graves眼病合并真菌性角膜感染1例

报道1例应用大剂量糖皮质激素治疗Graves眼病后导致的真菌性角膜感染。一位31岁的甲状腺机能亢进同时伴有双眼突出的女性,视力下降、眼睑浮肿。首先应用抗甲状腺药物(甲巯咪唑),1个月后,突眼症状无改善,遂给予大剂量甲强龙冲击和曲安奈德球后注射以减轻症状。3个月后,该患者出现角膜溃疡,双眼无光感。1周后体温升高,最高达39.5℃,给予抗菌治疗后体温仍波动在36.7～37.3℃之间。角膜溃疡分泌物涂片可见真菌芽孢和菌丝,予甲亢、抗真菌和营养支持治疗。1个月后,患者双眼睑浮肿减轻、角膜溃疡面积减少,视力恢复到可有光感,体温降至正常。     

内镜下萨氏扩张器扩张联合局部注射曲安奈德治疗食管良性吻合口狭窄的疗效及安全性研究

目的:探讨食管良性吻合口狭窄经内镜下萨氏扩张器扩张联合局部注射曲安奈德治疗的临床疗效及安全性。方法:选取79例食管良性吻合口狭窄患者作为研究对象,根据数字表法将其随机分为对照组(n=38)和研究组(n=41),对照组给予内镜下萨氏扩张器扩张治疗,研究组在对照组基础上联合局部注射曲安奈德治疗,比较两组患者临床疗效、术后恢复情况以及安全性。结果:研究组治疗后总有效率为85.37%(35/41),高于对照组患者的65.79%(25/38)(x~2=4.138,P=0.002)。研究组持续症状缓解时间、再次进行内镜下扩张治疗的间隔时间均长于对照组(t=21.573、27.209,P=0.000、0.000),两组患者治疗前Stooler评分比较差异无统计学意义(t=0.266,P=0.791),两组患者治疗后Stooler评分均降低(t=16.606、25.962,P=0.000、0.000),且研究组低于对照组(t=7.407,P=0.000)。研究组术后并发症总发生率为19.51%(8/41),低于对照组患者的42.11%(16/38)(x~2=4.760,P=0.009)。结论:食管良性吻合口狭窄经内镜下萨氏扩张器扩张联合局部注射曲安奈德治疗后,可获得较好的疗效,患者临床症状得到改善,同时还可减少并发症发生率,临床应用价值较高。     

Efficacy and Safety of Intravitreal Therapy in Macular Edema Due to Branch and Central Retinal Vein Occlusion: a Systematic Review

Background

Intravitreal agents have replaced observation in macular edema in central (CRVO) and grid laser photocoagulation in branch retinal vein occlusion (BRVO). We conducted a systematic review to evaluate efficacy and safety outcomes of intravitreal therapies for macular edema in CRVO and BRVO.

Methods

And Findings: MEDLINE, Embase, and the Cochrane Library were systematically searched for RCTs with no limitations of language and year of publication. 11 RCTs investigating anti-VEGF agents (ranibizumab, bevacizumab, aflibercept) and steroids (triamcinolone, dexamethasone implant) with a minimum follow-up of 1 year were evaluated.

Efficacy: CRVO

Greatest gain in visual acuity after 12 months was observed both under aflibercept 2 mg: +16.2 letters (8.5 injections), and under bevacizumab 1.25 mg: +16.1 letters (8 injections). Ranibizumab 0.5 mg improved vision by +13.9 letters (8.8 injections). Triamcinolone 1 mg and 4 mg stabilized visual acuity at a lower injection frequency (-1.2 letters, 2 injections).

BRVO

Ranibizumab 0.5 mg resulted in a visual acuity gain of +18.3 letters (8.4 injections). The effect of dexamethasone implant was transient after 1.9 implants in both indications.

Safety

Serious ocular adverse events were rare, e.g., endophthalmitis occurred in 0.0-0.9%. Major differences were found in an indirect comparison between steroids and anti-VEGF agents for cataract progression (19.8-35.0% vs. 0.9-7.0%) and in required treatment of increased intraocular pressure (7.0-41.0% vs. none). No major differences were identified in systemic adverse events.

Conclusions

Anti-VEGF agents result in a promising gain of visual acuity, but require a high injection frequency. Dexamethasone implant might be an alternative, but comparison is impaired as the effect is temporary and it has not yet been tested in PRN regimen. The ocular risk profile seems to be favorable for anti-VEGF agents in comparison to steroids. Because comparative data from head-to-head trials are missing currently, clinicians and patients should carefully weigh the benefit-harm ratio.     

Preliminary histopathological study of intra-articular injection of a novel highly cross-linked hyaluronic acid in a rabbit model of knee osteoarthritis

Osteoarthritis is a degenerative joint disease mostly occurring in the knee and commonly seen in middle-aged and elderly adults. Intra-articular injection of hyaluronic acid has been widely used for treatment of knee osteoarthritis. The aim of this study was to evaluate the efficacy of intra-articular injection of a novel highly cross-linked hyaluronic acid, alone or in combination with ropivacaine hydrochloride and triamcinolone acetonide, on knee articular cartilage in a rabbit model of collagenase-induced knee osteoarthritis. After induction of experimental osteoarthritis by intra-articular injection of collagenase, adult New Zealand white rabbits (n = 12) were divided into 3 groups. Group 1 (control group) received 0.3 ml phosphate buffered saline into the right knee joint. Group 2 received 0.3 ml cross-linked hyaluronic acid (33 mg/ml) into the right knee joint. Group 3 received a mixture of 0.15 ml cross-linked hyaluronic acid (33 mg/ml), 0.05 ml ropivacaine hydrochloride 1 % and 0.1 ml triamcinolone acetonide (10 mg/ml) into the right knee joint. Intra-articular injections were given 4 weeks after first collagenase injection and were administered once a week for 3 weeks. Gross pathology and histological evaluation of rabbits’ knee joints were performed after 16 weeks following initial collagenase injection. Histological analysis of sections of right knee joints at lesion sites showed a significant decrease in Mankin’s score in groups treated with hyaluronic acid alone or in combination with ropivacaine hydrochloride and triamcinolone acetonide versus control group (p < 0.05 and p < 0.01 respectively). This evidence was consistent with strong articular degenerative changes in control right knee joints (grade III osteoarthritis), while the treated groups revealed less severe articular degenerative changes (grade II osteoarthritis). The present results show that cross-linked hyaluronic acid, alone or in combination with ropivacaine hydrochloride and triamcinolone acetonide, produces a significant improvement in knee articular cartilage degeneration in a rabbit model of collagenase-induced osteoarthritis.     

Effect of topically applied steroidal and nonsteroidal anti-inflammatory agents on skin repair and regeneration

We studied the effects of topically applied steroidal and nonsteroidal anti-inflammatory agents on dermal and epidermal wound healing. Superficial wounds (0.3 mm deep) on the skin of domestic pigs were treated daily with either 0.1% triamcinolone acetonide (TA), 1% hydrocortisone (HC), 1% nandrolone decanoate (ND), 1% ND + 0.1% TA, 10 mg ibuprofen, 10 mg meclofenamate sodium, 3 mg indomethacin, vehicle (USP petrolatum or 70% ethanol), or control (untreated). Wounds were excised on days 2-7 after wounding and the epidermis was separated from the dermis. The dermis was assayed for collagen biosynthesis and the epidermis was evaluated for reepithelialization. A significant decrease (P less than 0.01) in relative collagen synthesis was observed in the wounded dermis in both HC- and TA-treated groups on day 3 after wounding, but there were no significant differences on days 4-7. Depressed collagen and noncollagenous protein production was also noted in vehicle-treated wounds on day 3. Topical application of ND did not affect collagen synthesis, but when combined with TA it eliminated the inhibitory effect observed as a result of TA alone. Topical ND accelerated wound reepithelialization by 12.5% compared with vehicle and by 26% compared with untreated controls. TA delayed epidermal resurfacing by 22%, but when combined with ND (ND + TA) the rate of reepithelialization was similar to vehicle-treated wounds. HC enhanced resurfacing when compared with untreated wounds but did not differ markedly from its vehicle. The nonsteroidal anti-inflammatory drugs when topically applied markedly reduced inflammation (erythema, heat, and edema) but did not influence the healing process.     

Characterization of steroid receptors in the gut and kidney of the frog (Rana catesbeiana) and in the gut of the turtle (Chrysemys picta)

Paraglucocorticoid- and paramineralocorticoid-binding cytosolic receptors (pGR, pMR) were demonstrated in the intestine and kidney of the frog, Rana catesbeiana and in the intestine of the turtle, Chrysemys picta, in the presence of sodium molybdate. These receptors were of high affinity and low capacity with the following binding parameters: pGR:Kd:frog intestine (FI), triamcinolone acetonide (TA): 3.3 nM, corticosterone (B): 3.4 nM; frog kidney (FK), TA:4.3 nM, B: 9.3 nM; turtle intestine (TI), TA: 4.8 nM; Nmax: FI, TA: 357, B: 371; FK, TA: 301, B: 157; TI, TA: 350 fmol/mg protein. pMR:Kd: FI, aldosterone: 0.9 and 90 nM (biphasic curves); FK, aldosterone: 0.6 and 36 nM (biphasic curves); Nmax: FI, 13 and 147 fmol/mg protein; FK, 78 and 109 fmol/mg protein. The receptor had the following ligand affinities: pGR: FI and FK: triamcinolone acetonide greater than DOC greater than 11 beta-hydroxyprogesterone greater than progesterone greater than corticosterone greater than cortisol greater than aldosterone greater than 11-dehydrocorticosterone greater than 17 alpha-hydroxyprogesterone greater than cortisone; TI: triamcinolone acetonide greater than corticosterone greater than progesterone greater than DOC greater than cortisol greater than aldosterone; pMR: FI and FK: corticosterone greater than 11 beta-hydroxyprogesterone greater than aldosterone greater than triamcinoline acetonide = cortisol greater than DOC greater than 11-dehydrocorticosterone greater than progesterone greater than 17 alpha-hydroxyprogesterone greater than cortisone. Androgens, estrogens or 18-hydroxycorticosterone did not compete for binding in either tissue. The heat activated frog receptors did not bind to naked DNA, though the turtle receptor did. It was possible to show that cytosol receptor-ligand complexes from all tissues were bound by nuclear acceptor sites. On linear sucrose gradients, the FI TA-receptor complex sediments with a single peak (7.5S), the FK TA-receptor complex gave two peaks (8.0 and 4.4S) and the TI TA-receptor complex showed a single peak (9.0S). The hydrodynamic parameters of the pGR's were determined by gel exclusion on Sephacel S-300. The following results were obtained: Mr: FI, 265, 80, 40 kDa (multiple proteins); FK, 280, 60, 20 kDa (multiple proteins); TI, 366 kDa; Rs: FI, 6.9, 3.9 nm; FK, 6.9, 2.9 nm; TI, 7.6 nm; f/f0: FI, 1.6; FK, 1.6; TI, 1.6. It is suggested on the basis of the binding and hydrodynamic parameters that non-mammalian epithelia corticosterone receptors have undergone biochemical evolution from one class of vertebrates to another.     

Glucocorticoid cytosol binding in exercise-induced sparing of muscle atrophy

Female rats were initially divided into a sedentary or an exercise group that was trained by treadmill running to a final work rate of 31 m/min, 100 min/day, for 13-18 wk. During the last 12 days of training each of these groups were further subdivided into groups that received daily subcutaneous injections of cortisol acetate (CA) (100 mg/kg body wt) or the vehicle (1% carboxymethyl cellulose). Exercise prevented approximately 40% of the gastrocnemius muscle weight loss due to CA treatment. Training did not influence glucocorticoid cytosol-receptor binding concentrations, using [3H]triamcinolone acetonide (TA) as the labeled glucocorticoid in any of the skeletal muscle types investigated. TA-receptor binding capacities were depleted by the multiple injections but were higher in the red fiber types of the CA-treated trained than those in the CA-treated sedentary animals. In a second series of experiments in which receptor depletion and repletion rates were studied using a single injection of cortisol, TA binding capacities 2 h after the cortisol injection were higher in slow-twitch red soleus muscles of trained as compared with sedentary rats (36.4 +/- 2.0 vs. 26.8 +/- 2.5 fmol/mg protein). Similar patterns of TA binding were also observed at 2 h between trained and sedentary animals in the fast-twitch red muscle types, whereas no training related differences were observed in white muscle types. Total and free serum cortisol concentrations also returned to base-line values faster in the trained animals following the single injection protocol.(ABSTRACT TRUNCATED AT 250 WORDS)